Survival from testicular cancer in england and wales up to 2001

British Journal of Cancer

Volumn 99, Issue , 2008, Pages S83-S85

  Huddart, R A ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; TUMOR MARKER;

AWARENESS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; EDUCATION; HUMAN; METASTASIS; NOTE; ORCHIECTOMY; OUTCOME ASSESSMENT; POPULATION; PRIORITY JOURNAL; PROGNOSIS; TESTIS CANCER; UNITED KINGDOM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ENGLAND; FORECASTING; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASMS, GERM CELL AND EMBRYONAL; SURVIVAL ANALYSIS; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; WALES;

EID: 52449107264     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604598     Document Type: Article

References (19)

1. Bhala N, Coleman JM, Radstone CR, Horsman JM, George J, Hancock BW, Hatton MQ, Coleman RE (2004) The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients. Clin Oncol (R Coll Radiol) 16: 40–47
2. Bhardwa JM, Powles T, Berney D, Baithun S, Nargund VH, Oliver RT (2005) Assessing the size and stage of testicular germ cell tumours: 1984–2003. BJU Int 96: 819–821
3. Bower M, Newlands E, Holden L, Rustin G, Begent R (1997) Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol 8: 477–483
4. Christian JA, Huddart RA, Norman A, Mason M, Fossa S, Aass N, Nicholl EJ, Dearnaley DP, Horwich A (2003) Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol 21: 871–877
5. Collette L, Sylvester R, Stenning S, Fossa S, Mead G, de Wit R, de Mulder P, Neymark N, Lallemand E, Kaye S (1999) Impact of the treating institution on survival of patients with ‘poor-prognosis’ metastatic nonseminoma. J Nat Cancer Inst 91: 839–846
6. Harding MJ, Paul J, Gillis CR, Kaye SB (1993) Management of malignant teratoma: does referral to a specialist unit matter? Lancet 314: 999–1002
7. Horwich A, Sleijfer DT, Fossa SD, Kaye SB, Oliver RT, Cullen MH, Mead GM, de Wit R, de Mulder PH, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP (1997) Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in goodprognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15: 1844–1852
8. Huddart RA (2003) Use of FDG-PET in testicular tumours. Clin Oncol (R Coll Radiol) 15: 123–127
9. Lackner JE, Koller A, Mazal PR, Waldert M, Waldhoer T, Marberger M, Kratzik C (2006) The changing distribution of pT stage in testicular germ cell tumours from 1976 to 2005: a single-centre analysis of histopathological reports. BJU Int 98: 747–750
10. Mayer F, Honecker F, Looijenga LH, Bokemeyer C (2003) Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors. Ann Oncol 14: 825–832
11. Mead GM, Stenning SP, Cook P, Fossa SD, Horwich A, Kaye SB, Oliver RTD, De Mulder PHM, De Wit R, Stoter G, Sylvester RJ, Bajorin DF, Bosl GJ, Mazumdar M, Nichols CR, Amato R, Pizzocaro G, Droz JP, Kramar A, Daugaard G, Cortes Funes H, Paz Ares L, Levi JA, Colls BM, Harvey VJ, Coppin C, Aass N, Clark PI, Cullen MH, Dearnaley D, Harland SJ, Jones WG, Newlands ES, Roberts JT, Rustin GJS, Wilkinson P, Read G, Williams MV, Sleijfer D, Huinink D, Motzer R, Finn L, Salviom R, Mariani L, Barragan PL, Hansen SW, Culine S, Bouzy J, Thompson D, Sandeman T, Gill PG, Byrne M, Perez JO, Thompson P, Bennet M, Murray N (1997) International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15: 594–603
12. Muramaki M, Hara I, Miyake H, Yamada Y, Kawabata G, Kamidono S (2004) Advances in the management of non-seminomatous germ cell tumors during the cisplatin era: a single-institution experience. Int J Urol 11: 768–773
13. Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, Fossa SD, Skakkebaek NE, de Wit R, Fizazi K, Droz JP, Pizzocaro G, Daugaard G, de Mulder PH, Horwich A, Oliver T, Huddart R, Rosti G, Paz Ares L, Pont O, Hartmann JT, Aass N, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Classen J, Clemm S, Culine S, de Wit M, Derigs HG, Dieckmann KP, Flasshove M, Garcia del Muro X, Gerl A, Germa-Lluch JR, Hartmann M, Heidenreich A, Hoeltl W, Joffe J, Jones W, Kaiser G, Klepp O, Kliesch S, Kisbenedek L, Koehrmann KU, Kuczyk M, Laguna MP, Leiva O, Loy V, Mason MD, Mead GM, Mueller RP, Nicolai N, Oosterhof GO, Pottek T, Rick O, Schmidberger H, Sedlmayer F, Siegert W, Studer U, Tjulandin S, von der Maase H, Walz P, Weinknecht S, Weissbach L, Winter E, Wittekind C (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15: 1377–1399
14. Sonneveld D, Hoekstra H, van de Graaf W, Sluiter W, Mulder N, Willemse P, Koops H, Sleijfer D (2001) Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer 91: 1304–1315
15. Sonneveld DJ, Hoekstra HJ, Van Der Graaf WT, Sluiter WJ, Schraffordt Koops H, Sleijfer DT (1999) The changing distribution of stage in nonseminomatous testicular germ cell tumours, from 1977 to 1996. BJU Int 84: 68–74
16. Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, Hall P, Holowaty E, Andersen A, Pukkala E, Andersson M, Kaijser M, Gospodarowicz M, Joensuu T, Cohen RJ, Boice Jr JD, Dores GM, Gilbert ES (2005) Second cancers among 40 576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97: 1354–1365
17. Vasudev NS, Joffe JK, Cooke C, Richards F, Jones WG (2004) Delay in the diagnosis of testicular tumours–changes over the past 18 years. Br J Gen Pract 54: 595–597
18. Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, von der Maase H (2002) Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 20: 4448–4452
19. Zagars GK, Ballo MT, Lee AK, Strom SS (2004) Mortality after cure of testicular seminoma. J Clin Oncol 22: 640–647